Meritain Eldorado policies

Search Meritain Eldorado's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

30 policies name J9060, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Meritain Eldorado policies
PolicyDetailsCodesSource
1020-Sodium Thiosulfate (Pedmark)1020 · Commercial3Original policy ↗
1071-Zolbetuximab-clzb (Vyloy)1071 · Commercial7Original policy ↗
0898-Necitumumab (Portrazza)0898 · Commercial8Original policy ↗
1080-Penpulimab-kcqx1080 · Commercial9Original policy ↗
0916-Avelumab (Bavencio)0916 · Commercial10Original policy ↗
1019-Tremelimumab-actl (Imjudo)1019 · Commercial10Original policy ↗
1021-Mirvetuximab Soravtansine-gynx (Elahere)1021 · Commercial10Original policy ↗
1049-Toripalimab-tpzi (Loqtorzi)1049 · Commercial11Original policy ↗
Cabazitaxel (Jevtana)0806 · Commercial13Original policy ↗
Hyperthermia in Cancer Therapy0278 · Commercial13Original policy ↗
0958-Gemcitabine0958 · Commercial14Original policy ↗
0995-Amivantamab-vmjw (Rybrevant) and Amivantamab and Hyaluronidase-lpuj (Rybrevant Faspro)0995 · Commercial15Original policy ↗
0834-Paclitaxel, Albumin-Bound0834 · Commercial16Original policy ↗
Enfortumab Vedotin-ejfv (Padcev)0967 · Commercial21Original policy ↗
Retifanlimab-dlwr (Zynyz)1030 · Commercial23Original policy ↗
0883-Ramucirumab (Cyramza)0883 · Commercial24Original policy ↗
0993-Dostarlimab-gxly (Jemperli)0993 · Commercial31Original policy ↗
0685-Bevacizumab for Non-Ocular Indications0685 · Commercial33Original policy ↗
Pemetrexed Products0687 · Commercial35Original policy ↗
0917-Durvalumab (Imfinzi)0917 · Commercial41Original policy ↗
Atezolizumab (Tecentriq) and Atezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza)0909 · Commercial46Original policy ↗
0978-Lurbinectedin (Zepzelca)0978 · Commercial53Original policy ↗
0892-Nivolumab Products (Opdivo, Opdivo Qvantig, and Opdualag)0892 · Commercial58Original policy ↗
0172-Hyperbaric Oxygen Therapy (HBOT)0172 · Commercial78Original policy ↗
0890-Pembrolizumab Products (Keytruda and Keytruda Qlex)0890 · Commercial82Original policy ↗
Tinnitus Treatments0406 · Commercial87Original policy ↗
Hematopoietic Colony-Stimulating Factors (CSFs)0055 · Commercial91Original policy ↗
0227-Breast and Ovarian Cancer Susceptibility Gene Testing, Prophylactic Mastectomy, and Prophylactic Oophorectomy0227 · Commercial103Original policy ↗
Antiemetic Therapy0724 · Commercial152Original policy ↗
0715-Pharmacogenetic Testing0715 · Commercial231Original policy ↗

Back to Meritain Eldorado

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.